Immphentiv is a drug owned by Hikma Pharmaceuticals Usa Inc. It is protected by 2 US drug patents filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 26, 2036. Details of Immphentiv's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11213480 | Phenylephrine hydrochloride ready-to-use solution |
Sep, 2036
(11 years from now) | Active |
| US11471400 | Phenylephrine hydrochloride ready-to-use solution |
Aug, 2036
(11 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Immphentiv's patents.
Latest Legal Activities on Immphentiv's Patents
Given below is the list of recent legal activities going on the following patents of Immphentiv.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation Critical | 18 Oct, 2022 | US11471400 |
| Recordation of Patent Grant Mailed Critical | 18 Oct, 2022 | US11471400 |
| Email Notification Critical | 29 Sep, 2022 | US11471400 |
| Issue Notification Mailed Critical | 28 Sep, 2022 | US11471400 |
| Dispatch to FDC | 13 Sep, 2022 | US11471400 |
| Application Is Considered Ready for Issue Critical | 13 Sep, 2022 | US11471400 |
| Issue Fee Payment Received Critical | 09 Sep, 2022 | US11471400 |
| Issue Fee Payment Verified Critical | 09 Sep, 2022 | US11471400 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 22 Jul, 2022 | US11471400 |
| Printer Rush- No mailing | 30 Jun, 2022 | US11471400 |
US patents provide insights into the exclusivity only within the United States, but Immphentiv is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Immphentiv's family patents as well as insights into ongoing legal events on those patents.
Immphentiv's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Immphentiv's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 26, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Immphentiv Generic API suppliers:
Phenylephrine Hydrochloride is the generic name for the brand Immphentiv. 16 different companies have already filed for the generic of Immphentiv, with Caplin having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Immphentiv's generic
Alternative Brands for Immphentiv
There are several other brand drugs using the same active ingredient (Phenylephrine Hydrochloride) as Immphentiv. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Eyenovia |
| |
| Paragon Bioteck |
| |
| Rayner Surgical |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Phenylephrine Hydrochloride, Immphentiv's active ingredient. Check the complete list of approved generic manufacturers for Immphentiv
About Immphentiv
Immphentiv is a drug owned by Hikma Pharmaceuticals Usa Inc. Immphentiv uses Phenylephrine Hydrochloride as an active ingredient. Immphentiv was launched by Hikma in 2023.
Approval Date:
Immphentiv was approved by FDA for market use on 09 March, 2023.
Active Ingredient:
Immphentiv uses Phenylephrine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Phenylephrine Hydrochloride ingredient
Dosage:
Immphentiv is available in solution form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 1MG/10ML (0.1MG/ML) | SOLUTION | Prescription | INTRAVENOUS |
| 0.5MG/5ML (0.1MG/ML) | SOLUTION | Prescription | INTRAVENOUS |